Skip to main content
Top
Published in: Neurotherapeutics 3/2023

01-04-2023 | Stroke | Review

The Future of Ischemic Stroke Diagnosis and a Review of Underrecognized Ischemic Stroke Etiologies

Author: Michelle C. Johansen

Published in: Neurotherapeutics | Issue 3/2023

Login to get access

Abstract

Accurate ischemic stroke etiologic determination and diagnosis form the foundation of excellent cerebrovascular care as from it stems initiation of the appropriate secondary prevention strategy as well as appropriate patient education regarding specific risk factors for that subtype. Recurrent stroke rates are highest among those patients who receive an incorrect initial stroke diagnosis. Patient distrust and patient reported depression are also higher. The cause of the ischemic stroke also informs predicted patient outcomes and the anticipated recovery trajectory. Finally, determining the accurate cause of the ischemic stroke provides the patient the opportunity to enroll in appropriate research studies studying mechanism, or targeting treatment approaches for that particular disease process. Advances in ischemic stroke research, imaging techniques, biomarkers, and the ability to rapidly perform genetic sequencing over the past decade have shown that classifying patients into large etiologic buckets may not always be appropriate and may represent one reason why some patients are labeled as cryptogenic, or for whom an underlying etiology is never found. Aside from the more traditional stroke mechanisms, there is new research emerging regarding clinical findings that are not normative, but the contributions to ischemic stroke are unclear. In this article, we first review the essential steps to accurate ischemic stroke etiologic classification and then transition to a discussion of embolic stroke of undetermined source (ESUS) and other new entities that have been postulated as causal in ischemic stroke (i.e., genetics and subclinical atherosclerosis). We also discuss the limitations that are inherent in the current ischemic stroke diagnostic algorithms and finally review the most recent studies regarding more uncommon diagnoses and the future of stroke diagnostics and classification.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke (1970). 2021;52(7):e364–467. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke (1970). 2021;52(7):e364–467.
2.
go back to reference Bushnell C, Siddiqi Z, Morgenlander JC, Goldstein LB. Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology. 2001;56(5):624–7.PubMedCrossRef Bushnell C, Siddiqi Z, Morgenlander JC, Goldstein LB. Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology. 2001;56(5):624–7.PubMedCrossRef
3.
go back to reference Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41.PubMedCrossRef Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41.PubMedCrossRef
4.
go back to reference Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007;38(11):2979–84.PubMedCrossRef Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007;38(11):2979–84.PubMedCrossRef
5.
go back to reference Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis. 2009;27(5):502–8.PubMedCrossRef Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis. 2009;27(5):502–8.PubMedCrossRef
6.
go back to reference Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis. 2013;36(1):1–5.PubMedCrossRef Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis. 2013;36(1):1–5.PubMedCrossRef
7.
go back to reference Arsava EM, Helenius J, Avery R, Sorgun MH, Kim G, Pontes-Neto OM, et al. Assessment of the predictive validity of etiologic stroke classification. JAMA Neurol. 2017;74(4):419–26.PubMedPubMedCentralCrossRef Arsava EM, Helenius J, Avery R, Sorgun MH, Kim G, Pontes-Neto OM, et al. Assessment of the predictive validity of etiologic stroke classification. JAMA Neurol. 2017;74(4):419–26.PubMedPubMedCentralCrossRef
8.
go back to reference Ay H, Arsava EM, Andsberg G, Benner T, Brown RD, Chapman SN, et al. Etiologic ischemic stroke phenotypes in the NINDS Stroke Genetics Network. Stroke (1970). 2014;45(12):3589–96.CrossRef Ay H, Arsava EM, Andsberg G, Benner T, Brown RD, Chapman SN, et al. Etiologic ischemic stroke phenotypes in the NINDS Stroke Genetics Network. Stroke (1970). 2014;45(12):3589–96.CrossRef
9.
go back to reference Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38.PubMedCrossRef Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38.PubMedCrossRef
10.
go back to reference Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.PubMedPubMedCentralCrossRef Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.PubMedPubMedCentralCrossRef
11.
go back to reference Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke (1970). 2015;46(8):2087–93.CrossRef Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke (1970). 2015;46(8):2087–93.CrossRef
12.
go back to reference Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. J Am Coll Cardiol. 2020;75(3):333–40.PubMedCrossRef Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. J Am Coll Cardiol. 2020;75(3):333–40.PubMedCrossRef
13.
go back to reference Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–72.PubMedCrossRef Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–72.PubMedCrossRef
14.
15.
go back to reference Yaghi S, Chang AD, Hung P, Mac Grory B, Collins S, Gupta A, et al. Left atrial appendage morphology and embolic stroke of undetermined source: a cross-sectional multicenter pilot study. J Stroke Cerebrovasc Dis. 2018;27(6):1497–501.PubMedCrossRef Yaghi S, Chang AD, Hung P, Mac Grory B, Collins S, Gupta A, et al. Left atrial appendage morphology and embolic stroke of undetermined source: a cross-sectional multicenter pilot study. J Stroke Cerebrovasc Dis. 2018;27(6):1497–501.PubMedCrossRef
16.
go back to reference Johansen MC, De Vasconcellos HD, Gottesman RF. Understanding atrial cardiopathy: an under-recognized contributor to cardioembolic stroke. Curr Treat Options Neurol. 2019;21(7):32–4.PubMedCrossRef Johansen MC, De Vasconcellos HD, Gottesman RF. Understanding atrial cardiopathy: an under-recognized contributor to cardioembolic stroke. Curr Treat Options Neurol. 2019;21(7):32–4.PubMedCrossRef
17.
go back to reference Maier IL, Schregel K, Karch A, Weber-Krueger M, Mikolajczyk RT, Stahrenberg R, et al. Association between embolic stroke patterns, ESUS etiology, and new diagnosis of atrial fibrillation: a secondary data analysis of the Find-AF trial. Stroke Res Treat. 2017;2017:1391843.PubMedPubMedCentral Maier IL, Schregel K, Karch A, Weber-Krueger M, Mikolajczyk RT, Stahrenberg R, et al. Association between embolic stroke patterns, ESUS etiology, and new diagnosis of atrial fibrillation: a secondary data analysis of the Find-AF trial. Stroke Res Treat. 2017;2017:1391843.PubMedPubMedCentral
18.
go back to reference Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke. 2015;46(8):2087–93.PubMedCrossRef Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke. 2015;46(8):2087–93.PubMedCrossRef
19.
go back to reference Sanna T, Diener H, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.PubMedCrossRef Sanna T, Diener H, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.PubMedCrossRef
20.
go back to reference Dalen JE, Alpert JS. Silent atrial fibrillation and cryptogenic strokes. Am J Med. 2017;130(3):264–7.PubMedCrossRef Dalen JE, Alpert JS. Silent atrial fibrillation and cryptogenic strokes. Am J Med. 2017;130(3):264–7.PubMedCrossRef
21.
22.
go back to reference Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, American Heart Association Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes Research, Stroke Council, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e623.PubMedPubMedCentralCrossRef Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, American Heart Association Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes Research, Stroke Council, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e623.PubMedPubMedCentralCrossRef
23.
go back to reference Arauz A, Morelos E, Colin J, Roldan J, Barboza MA. Comparison of functional outcome and stroke recurrence in patients with embolic stroke of undetermined source (ESUS) vs. cardioembolic stroke patients. PLoS ONE. 2016;11(11):e0166091.PubMedPubMedCentralCrossRef Arauz A, Morelos E, Colin J, Roldan J, Barboza MA. Comparison of functional outcome and stroke recurrence in patients with embolic stroke of undetermined source (ESUS) vs. cardioembolic stroke patients. PLoS ONE. 2016;11(11):e0166091.PubMedPubMedCentralCrossRef
24.
go back to reference Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.PubMedCrossRef Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.PubMedCrossRef
25.
go back to reference Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.PubMedCrossRef Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.PubMedCrossRef
26.
go back to reference Hohnloser SH, Capucci A, Fain E, Gold MR, van Gelder IC, Healey J, et al. Asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial (ASSERT). Am Heart J. 2006;152(3):442–7.PubMedCrossRef Hohnloser SH, Capucci A, Fain E, Gold MR, van Gelder IC, Healey J, et al. Asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial (ASSERT). Am Heart J. 2006;152(3):442–7.PubMedCrossRef
27.
go back to reference Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8(9):1416–23.PubMedCrossRef Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8(9):1416–23.PubMedCrossRef
28.
go back to reference Swiryn S, Orlov M, Benditt D, DiMarco J, Lloyd-Jones D, Karst E, et al. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes. Circulation (New York, NY). 2016;134(16):1130–40. Swiryn S, Orlov M, Benditt D, DiMarco J, Lloyd-Jones D, Karst E, et al. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes. Circulation (New York, NY). 2016;134(16):1130–40.
29.
go back to reference Bosi GM, Cook A, Rai R, Menezes LJ, Schievano S, Torii R, et al. Computational fluid dynamic analysis of the left atrial appendage to predict thrombosis risk. Front Cardiovasc Med. 2018;4(5):34.CrossRef Bosi GM, Cook A, Rai R, Menezes LJ, Schievano S, Torii R, et al. Computational fluid dynamic analysis of the left atrial appendage to predict thrombosis risk. Front Cardiovasc Med. 2018;4(5):34.CrossRef
30.
go back to reference Elkind MSV. Atrial cardiopathy and stroke prevention. Curr Cardiol Rep. 2018;20(11):1–14.CrossRef Elkind MSV. Atrial cardiopathy and stroke prevention. Curr Cardiol Rep. 2018;20(11):1–14.CrossRef
31.
go back to reference Kamel H, Okin PM, Longstreth WT Jr, Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015;11(3):323–31.PubMedCrossRef Kamel H, Okin PM, Longstreth WT Jr, Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015;11(3):323–31.PubMedCrossRef
33.
go back to reference Yamamoto M, Seo Y, Kawamatsu N, Sato K, Sugano A, Machino-Ohtsuka T, et al. Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation. Circ Cardiovasc Imaging. 2014;7(2):337–43.PubMedCrossRef Yamamoto M, Seo Y, Kawamatsu N, Sato K, Sugano A, Machino-Ohtsuka T, et al. Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation. Circ Cardiovasc Imaging. 2014;7(2):337–43.PubMedCrossRef
34.
go back to reference Yesilot Barlas N, Putaala J, Waje-Andreassen U, Vassilopoulou S, Nardi K, Odier C, et al. Etiology of first-ever ischaemic stroke in European young adults: the 15 cities young stroke study. Eur J Neurol. 2013;20(11):1431–9.PubMed Yesilot Barlas N, Putaala J, Waje-Andreassen U, Vassilopoulou S, Nardi K, Odier C, et al. Etiology of first-ever ischaemic stroke in European young adults: the 15 cities young stroke study. Eur J Neurol. 2013;20(11):1431–9.PubMed
35.
go back to reference Putaala J, Curtze S, Hiltunen S, Tolppanen H, Kaste M, Tatlisumak T. Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke. 2009;40(8):2698–703.PubMedCrossRef Putaala J, Curtze S, Hiltunen S, Tolppanen H, Kaste M, Tatlisumak T. Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke. 2009;40(8):2698–703.PubMedCrossRef
36.
go back to reference Rutten-Jacobs LC, Maaijwee NA, Arntz RM, Schoonderwaldt HC, Dorresteijn LD, van der Vlugt MJ, et al. Long-term risk of recurrent vascular events after young stroke: the FUTURE study. Ann Neurol. 2013;74(4):592–601.PubMedCrossRef Rutten-Jacobs LC, Maaijwee NA, Arntz RM, Schoonderwaldt HC, Dorresteijn LD, van der Vlugt MJ, et al. Long-term risk of recurrent vascular events after young stroke: the FUTURE study. Ann Neurol. 2013;74(4):592–601.PubMedCrossRef
37.
go back to reference Johansen MC, Gottesman RF. Cerebrovascular disease and cognitive outcome in patients with cardiac disease. Semin Neurol. 2021. Johansen MC, Gottesman RF. Cerebrovascular disease and cognitive outcome in patients with cardiac disease. Semin Neurol. 2021.
38.
go back to reference Wang W, Zhang MJ, Inciardi RM, Norby FL, Johansen MC, Parikh R, et al. Association of echocardiographic measures of left atrial function and size with incident dementia. JAMA. 2022;327(12):1138–48.PubMedPubMedCentralCrossRef Wang W, Zhang MJ, Inciardi RM, Norby FL, Johansen MC, Parikh R, et al. Association of echocardiographic measures of left atrial function and size with incident dementia. JAMA. 2022;327(12):1138–48.PubMedPubMedCentralCrossRef
39.
go back to reference Johansen MC, Wang W, Zhang M, Knopman DS, Ndumele C, Mosley TH, et al. Risk of Dementia associated with atrial cardiopathy: the ARIC study. J Am Heart Assoc. 2022;11(16):e025646.PubMedPubMedCentralCrossRef Johansen MC, Wang W, Zhang M, Knopman DS, Ndumele C, Mosley TH, et al. Risk of Dementia associated with atrial cardiopathy: the ARIC study. J Am Heart Assoc. 2022;11(16):e025646.PubMedPubMedCentralCrossRef
40.
go back to reference Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17.PubMedCrossRef Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17.PubMedCrossRef
41.
go back to reference Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nagele T, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke. 2017;12(9):985–90.PubMedCrossRef Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nagele T, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke. 2017;12(9):985–90.PubMedCrossRef
42.
go back to reference Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14(2):207–14.PubMedCrossRef Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14(2):207–14.PubMedCrossRef
43.
go back to reference Rutten JW, Van Eijsden BJ, Duering M, Jouvent E, Opherk C, Pantoni L, et al. The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1–6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7–34 pathogenic variant. Genet Med. 2019;21(3):676–82.PubMedCrossRef Rutten JW, Van Eijsden BJ, Duering M, Jouvent E, Opherk C, Pantoni L, et al. The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1–6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7–34 pathogenic variant. Genet Med. 2019;21(3):676–82.PubMedCrossRef
44.
go back to reference Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L, et al. CADASIL and CARASIL. Brain Pathol (Zurich, Switzerland). 2014;24(5):525–44.CrossRef Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L, et al. CADASIL and CARASIL. Brain Pathol (Zurich, Switzerland). 2014;24(5):525–44.CrossRef
45.
go back to reference Ringelstein EB, Kleffner I, Dittrich R, Kuhlenbäumer G, Ritter MA. Hereditary and non-hereditary microangiopathies in the young. An up-date. J Neurol Sci. 2010;299(1):81–5.PubMedCrossRef Ringelstein EB, Kleffner I, Dittrich R, Kuhlenbäumer G, Ritter MA. Hereditary and non-hereditary microangiopathies in the young. An up-date. J Neurol Sci. 2010;299(1):81–5.PubMedCrossRef
46.
go back to reference Tapia D, Kimonis V. Stroke and chronic kidney disease in Fabry disease. J Stroke Cerebrovasc Dis. 2021;30(9):105423.PubMedCrossRef Tapia D, Kimonis V. Stroke and chronic kidney disease in Fabry disease. J Stroke Cerebrovasc Dis. 2021;30(9):105423.PubMedCrossRef
47.
go back to reference Uemura M, Nozaki H, Kato T, Koyama A, Sakai N, Ando S, et al. HTRA1-related cerebral small vessel disease: a review of the literature. Front Neurol. 2020;11:545.PubMedPubMedCentralCrossRef Uemura M, Nozaki H, Kato T, Koyama A, Sakai N, Ando S, et al. HTRA1-related cerebral small vessel disease: a review of the literature. Front Neurol. 2020;11:545.PubMedPubMedCentralCrossRef
48.
go back to reference Debette S, Markus HS. Stroke genetics: discovery, insight into mechanisms, and clinical perspectives. Circ Res. 2022;130(8):1095–111.PubMedCrossRef Debette S, Markus HS. Stroke genetics: discovery, insight into mechanisms, and clinical perspectives. Circ Res. 2022;130(8):1095–111.PubMedCrossRef
49.
go back to reference Dichgans M, Beaufort N, Debette S, Anderson CD. Stroke genetics: turning discoveries into clinical applications. Stroke (1970). 2021;52(9):2974–82.CrossRef Dichgans M, Beaufort N, Debette S, Anderson CD. Stroke genetics: turning discoveries into clinical applications. Stroke (1970). 2021;52(9):2974–82.CrossRef
50.
go back to reference Abraham G, Malik R, Yonova-Doing E, Salim A, Wang T, Danesh J, et al. Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke. Nat Commun. 2019;10(1):5819.PubMedPubMedCentralCrossRef Abraham G, Malik R, Yonova-Doing E, Salim A, Wang T, Danesh J, et al. Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke. Nat Commun. 2019;10(1):5819.PubMedPubMedCentralCrossRef
51.
go back to reference Abbott AL, Paraskevas KI, Kakkos SK, Golledge J, Eckstein HH, Diaz-Sandoval LJ, Cao L, et al. Systematic review of guidelines for the management of asymptomatic and symptomatic carotid stenosis. Stroke 2015;46(11):3288–3301. Abbott AL, Paraskevas KI, Kakkos SK, Golledge J, Eckstein HH, Diaz-Sandoval LJ, Cao L, et al. Systematic review of guidelines for the management of asymptomatic and symptomatic carotid stenosis. Stroke 2015;46(11):3288–3301.
52.
go back to reference Turan T, Voeks JH, Chimowitz MI. Rationale, design, and implementation of intensive risk factor treatment in the CREST2 trial. J Vasc Surg. 2021;73(2):733.CrossRef Turan T, Voeks JH, Chimowitz MI. Rationale, design, and implementation of intensive risk factor treatment in the CREST2 trial. J Vasc Surg. 2021;73(2):733.CrossRef
53.
go back to reference Kopczak A, Schindler A, Bayer-Karpinska A, Koch ML, Sepp D, Zeller J, et al. Complicated carotid artery plaques as a cause of cryptogenic stroke. J Am Coll Cardiol. 2020;76(19):2212–22.PubMedCrossRef Kopczak A, Schindler A, Bayer-Karpinska A, Koch ML, Sepp D, Zeller J, et al. Complicated carotid artery plaques as a cause of cryptogenic stroke. J Am Coll Cardiol. 2020;76(19):2212–22.PubMedCrossRef
54.
go back to reference Bayer-Karpinska A, Schwarz F, Wollenweber FA, Poppert H, Boeckh-Behrens T, Becker A, et al. The carotid plaque imaging in acute stroke (CAPIAS) study: protocol and initial baseline data. BMC Neurol. 2013;13(1):201.PubMedPubMedCentralCrossRef Bayer-Karpinska A, Schwarz F, Wollenweber FA, Poppert H, Boeckh-Behrens T, Becker A, et al. The carotid plaque imaging in acute stroke (CAPIAS) study: protocol and initial baseline data. BMC Neurol. 2013;13(1):201.PubMedPubMedCentralCrossRef
55.
go back to reference Perera KS, Vanassche T, Bosch J, Giruparajah M, Swaminathan B, Mattina KR, et al. Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry. Int J Stroke. 2016;11(5):526–33.PubMedCrossRef Perera KS, Vanassche T, Bosch J, Giruparajah M, Swaminathan B, Mattina KR, et al. Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry. Int J Stroke. 2016;11(5):526–33.PubMedCrossRef
56.
go back to reference Naylor AR, Ricco J-B, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor’s Choice – Management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(1):3–81.PubMedCrossRef Naylor AR, Ricco J-B, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor’s Choice – Management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(1):3–81.PubMedCrossRef
57.
go back to reference Saba L, Agarwal N, Cau R, Gerosa C, Sanfilippo R, Porcu M, et al. Review of imaging biomarkers for the vulnerable carotid plaque. JVS-Vascular Science. 2021;2:149–58. PubMedPubMedCentralCrossRef Saba L, Agarwal N, Cau R, Gerosa C, Sanfilippo R, Porcu M, et al. Review of imaging biomarkers for the vulnerable carotid plaque. JVS-Vascular Science. 2021;2:149–58. PubMedPubMedCentralCrossRef
58.
go back to reference Camps-Renom P, McCabe J, Martí-Fàbregas J, Giannotti N, Fernández-León A, McNulty JP, et al. Association of plaque inflammation with stroke recurrence in patients with unproven benefit from carotid revascularization. Neurology. 2022;10. Camps-Renom P, McCabe J, Martí-Fàbregas J, Giannotti N, Fernández-León A, McNulty JP, et al. Association of plaque inflammation with stroke recurrence in patients with unproven benefit from carotid revascularization. Neurology. 2022;10.
59.
go back to reference Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(5):476–81.PubMedCrossRef Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(5):476–81.PubMedCrossRef
60.
go back to reference Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A III, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38(12):3198–204.PubMedCrossRef Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A III, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38(12):3198–204.PubMedCrossRef
61.
go back to reference Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRef Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRef
62.
go back to reference Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.PubMedCrossRef Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.PubMedCrossRef
63.
go back to reference Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, et al. Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis. Stroke. 2019;50(9):2477–85.PubMedCrossRef Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, et al. Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis. Stroke. 2019;50(9):2477–85.PubMedCrossRef
64.
go back to reference Selvik HA, Thomassen L, Logallo N, Næss H. Prior cancer in patients with ischemic stroke: the Bergen NORSTROKE study. J Stroke Cerebrovasc Dis. 2014;23(5):919–25.PubMedCrossRef Selvik HA, Thomassen L, Logallo N, Næss H. Prior cancer in patients with ischemic stroke: the Bergen NORSTROKE study. J Stroke Cerebrovasc Dis. 2014;23(5):919–25.PubMedCrossRef
65.
go back to reference Sanossian N, Djabiras C, Mack WJ, Ovbiagele B. Trends in Cancer diagnoses among inpatients hospitalized with stroke. J Stroke Cerebrovasc Dis. 2013;22(7):1146–50.PubMedCrossRef Sanossian N, Djabiras C, Mack WJ, Ovbiagele B. Trends in Cancer diagnoses among inpatients hospitalized with stroke. J Stroke Cerebrovasc Dis. 2013;22(7):1146–50.PubMedCrossRef
66.
go back to reference Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, et al. Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke. Stroke. 2014;45(8):2292–7.PubMedPubMedCentralCrossRef Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, et al. Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke. Stroke. 2014;45(8):2292–7.PubMedPubMedCentralCrossRef
67.
go back to reference Navi BB, Sherman CP, Genova R, Mathias R, Lansdale KN, LeMoss NM, et al. Mechanisms of ischemic stroke in patients with cancer: a prospective study. Ann Neurol. 2021;90(1):159–69.PubMedPubMedCentralCrossRef Navi BB, Sherman CP, Genova R, Mathias R, Lansdale KN, LeMoss NM, et al. Mechanisms of ischemic stroke in patients with cancer: a prospective study. Ann Neurol. 2021;90(1):159–69.PubMedPubMedCentralCrossRef
70.
go back to reference Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;74(4):567–77.PubMedPubMedCentralCrossRef Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;74(4):567–77.PubMedPubMedCentralCrossRef
71.
go back to reference Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;29(2):788–97.CrossRef Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;29(2):788–97.CrossRef
72.
go back to reference Merkler AE, Navi BB, Singer S, Cheng NT, Stone JB, Kamel H, et al. Diagnostic yield of echocardiography in cancer patients with ischemic stroke. J Neurooncol. 2015;123(1):115–21.PubMedPubMedCentralCrossRef Merkler AE, Navi BB, Singer S, Cheng NT, Stone JB, Kamel H, et al. Diagnostic yield of echocardiography in cancer patients with ischemic stroke. J Neurooncol. 2015;123(1):115–21.PubMedPubMedCentralCrossRef
73.
go back to reference Salazar-Camelo RA, Moreno-Vargas EA, Cardona AF, Bayona-Ortiz HF. Ischemic stroke: a paradoxical manifestation of cancer. Crit Rev Oncol. 2021;157: 103181.CrossRef Salazar-Camelo RA, Moreno-Vargas EA, Cardona AF, Bayona-Ortiz HF. Ischemic stroke: a paradoxical manifestation of cancer. Crit Rev Oncol. 2021;157: 103181.CrossRef
74.
go back to reference Gon Y, Okazaki S, Terasaki Y, Sasaki T, Yoshimine T, Sakaguchi M, et al. Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016;3(4):280–7.PubMedPubMedCentralCrossRef Gon Y, Okazaki S, Terasaki Y, Sasaki T, Yoshimine T, Sakaguchi M, et al. Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016;3(4):280–7.PubMedPubMedCentralCrossRef
75.
go back to reference Dardiotis E, Aloizou A, Markoula S, Siokas V, Tsarouhas K, Tzanakakis G, et al. Cancer-associated stroke: pathophysiology, detection and management. Int J Oncol. 2019;54(3):779–96.PubMedPubMedCentral Dardiotis E, Aloizou A, Markoula S, Siokas V, Tsarouhas K, Tzanakakis G, et al. Cancer-associated stroke: pathophysiology, detection and management. Int J Oncol. 2019;54(3):779–96.PubMedPubMedCentral
76.
go back to reference Morris B, Partap S, Yeom K, Gibbs IC, Fisher PG, King AA. Cerebrovascular disease in childhood cancer survivors: a Children’s Oncology Group report. Neurology. 2009;73(22):1906–13.PubMedPubMedCentralCrossRef Morris B, Partap S, Yeom K, Gibbs IC, Fisher PG, King AA. Cerebrovascular disease in childhood cancer survivors: a Children’s Oncology Group report. Neurology. 2009;73(22):1906–13.PubMedPubMedCentralCrossRef
77.
go back to reference Campen CJ, Kranick SM, Kasner SE, Kessler SK, Zimmerman RA, Lustig R, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012;43(11):3035–40.PubMedPubMedCentralCrossRef Campen CJ, Kranick SM, Kasner SE, Kessler SK, Zimmerman RA, Lustig R, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012;43(11):3035–40.PubMedPubMedCentralCrossRef
78.
go back to reference Kitano T, Sasaki T, Gon Y, Todo K, Okazaki S, Kitamura T, et al. The effect of chemotherapy on stroke risk in cancer patients. Thromb Haemost. 2020;120(04):714–23.PubMedCrossRef Kitano T, Sasaki T, Gon Y, Todo K, Okazaki S, Kitamura T, et al. The effect of chemotherapy on stroke risk in cancer patients. Thromb Haemost. 2020;120(04):714–23.PubMedCrossRef
79.
go back to reference Zuo P, Chen X, Liu Y, Xiao C, Liu C. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS ONE. 2014;9(7):e102484.PubMedPubMedCentralCrossRef Zuo P, Chen X, Liu Y, Xiao C, Liu C. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS ONE. 2014;9(7):e102484.PubMedPubMedCentralCrossRef
80.
go back to reference Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–311.PubMedPubMedCentralCrossRef Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–311.PubMedPubMedCentralCrossRef
81.
go back to reference Rioux B, Touma L, Nehme A, Gore G, Keezer MR, Gioia LC. Frequency and predictors of occult cancer in ischemic stroke: a systematic review and meta-analysis. Int J Stroke. 2021;16(1):12–9.PubMedCrossRef Rioux B, Touma L, Nehme A, Gore G, Keezer MR, Gioia LC. Frequency and predictors of occult cancer in ischemic stroke: a systematic review and meta-analysis. Int J Stroke. 2021;16(1):12–9.PubMedCrossRef
82.
go back to reference Seok JM, Kim SG, Kim JW, Chung C, Kim G, Lee KH, et al. Coagulopathy and embolic signal in cancer patients with ischemic stroke. Ann Neurol. 2010;68(2):213–9.PubMed Seok JM, Kim SG, Kim JW, Chung C, Kim G, Lee KH, et al. Coagulopathy and embolic signal in cancer patients with ischemic stroke. Ann Neurol. 2010;68(2):213–9.PubMed
83.
go back to reference Selvik HA, Bjerkreim AT, Thomassen L, Waje-Andreassen U, Naess H, Kvistad CE. When to screen ischaemic stroke patients for cancer. Cerebrovasc Dis. 2018;45(1–2):42–7.PubMedCrossRef Selvik HA, Bjerkreim AT, Thomassen L, Waje-Andreassen U, Naess H, Kvistad CE. When to screen ischaemic stroke patients for cancer. Cerebrovasc Dis. 2018;45(1–2):42–7.PubMedCrossRef
84.
go back to reference Rost NS, Brodtmann A, Pase MP, van Veluw SJ, Biffi A, Duering M, et al. Post-stroke cognitive impairment and dementia. Circ Res. 2022;130(8):1252–71.PubMedCrossRef Rost NS, Brodtmann A, Pase MP, van Veluw SJ, Biffi A, Duering M, et al. Post-stroke cognitive impairment and dementia. Circ Res. 2022;130(8):1252–71.PubMedCrossRef
85.
go back to reference Maniega SM, Hernández MCV, Clayden JD, Royle NA, Murray C, Morris Z, et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging. 2015;36(2):909–18.PubMedPubMedCentralCrossRef Maniega SM, Hernández MCV, Clayden JD, Royle NA, Murray C, Morris Z, et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging. 2015;36(2):909–18.PubMedPubMedCentralCrossRef
86.
go back to reference Ghaznawi R, Geerlings MI, Jaarsma-Coes M, Hendrikse J, de Bresser J, UCC-Smart Study Group. Association of white matter hyperintensity markers on MRI and long-term risk of mortality and ischemic stroke: the SMART-MR study. Neurology. 2021;96(17):e2172–83.PubMedPubMedCentralCrossRef Ghaznawi R, Geerlings MI, Jaarsma-Coes M, Hendrikse J, de Bresser J, UCC-Smart Study Group. Association of white matter hyperintensity markers on MRI and long-term risk of mortality and ischemic stroke: the SMART-MR study. Neurology. 2021;96(17):e2172–83.PubMedPubMedCentralCrossRef
87.
go back to reference Wardlaw JM, Debette S, Jokinen H, De Leeuw F, Pantoni L, Chabriat H, et al. ESO guideline on covert cerebral small vessel disease. Eur Stroke J. 2021;6(2):CXI–CLXII.PubMedPubMedCentralCrossRef Wardlaw JM, Debette S, Jokinen H, De Leeuw F, Pantoni L, Chabriat H, et al. ESO guideline on covert cerebral small vessel disease. Eur Stroke J. 2021;6(2):CXI–CLXII.PubMedPubMedCentralCrossRef
88.
go back to reference Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33(1):21–5.PubMedCrossRef Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33(1):21–5.PubMedCrossRef
89.
go back to reference Anand SS, Tu JV, Desai D, Awadalla P, Robson P, Jacquemont S, et al. Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. Eur Heart J Cardiovasc Imaging. 2020;21(6):692–700.PubMedCrossRef Anand SS, Tu JV, Desai D, Awadalla P, Robson P, Jacquemont S, et al. Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. Eur Heart J Cardiovasc Imaging. 2020;21(6):692–700.PubMedCrossRef
90.
go back to reference Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014;12(1):1–11.CrossRef Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014;12(1):1–11.CrossRef
91.
go back to reference Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond). 2017;131(11):1059–68.PubMedCrossRef Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond). 2017;131(11):1059–68.PubMedCrossRef
Metadata
Title
The Future of Ischemic Stroke Diagnosis and a Review of Underrecognized Ischemic Stroke Etiologies
Author
Michelle C. Johansen
Publication date
01-04-2023
Publisher
Springer International Publishing
Keyword
Stroke
Published in
Neurotherapeutics / Issue 3/2023
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-023-01383-3

Other articles of this Issue 3/2023

Neurotherapeutics 3/2023 Go to the issue